Eleven Biotherapeutics Inc. (EBIO) Trading 3.1% Higher
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 3.1% during mid-day trading on Tuesday . The company traded as high as $3.50 and last traded at $3.35, with a volume of 1,373,021 shares changing hands. The stock had previously closed at $3.25.
The stock’s 50 day moving average price is $4.45 and its 200 day moving average price is $2.18. The firm’s market capitalization is $51.87 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. Analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/eleven-biotherapeutics-inc-ebio-trading-3-1-higher.html
In other news, major shareholder Ventures Fund 2007 L. Flagship sold 46,692 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $4.18, for a total value of $195,172.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ventures Fund 2007 L. Flagship sold 129,497 shares of the company’s stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $4.54, for a total value of $587,916.38. The disclosure for this sale can be found here. 28.70% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Flagship Ventures Fund 2007 L.P. acquired a new position in Eleven Biotherapeutics during the first quarter worth $610,000. Sabby Management LLC raised its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares during the period. Flagship Ventures Fund IV L.P. acquired a new position in Eleven Biotherapeutics during the first quarter worth $469,000. Boxer Capital LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth $1,670,000. Finally, Flagship Ventures Fund IV General Partner LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth $2,464,000. 24.81% of the stock is owned by hedge funds and other institutional investors.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.